Quest Diagnostics Inc

Quest Diagnostics’ stock climbs to a new all‑time high, fueled by rising diagnostic demand, automation gains, and a strong market moat—discover how the lab giant’s strategy secures continued growth and resilient margins.

Quest Diagnostics stays steady in a shifting lab‑services market—leveraging automation, high‑margin specialty tests and digital integration to boost efficiency, margins, and patient reach.

Quest Diagnostics’ QDX stock sits mid‑range with solid PE, steady growth, and a broad lab network poised for precision‑medicine expansion—ideal for investors eyeing resilient healthcare testing.

Quest Diagnostics reveals 96%‑sensitive Haystack MRD® assay data at ASCO 2026 and a new Corewell Health joint‑venture, boosting precision oncology and lab efficiency.

Quest Diagnostics’ latest Q4 shows solid growth, low P/E, strong EBITDA, and strategic digital expansion—key insights for investors and healthcare providers.

Quest Diagnostics’ latest earnings reveal steady growth, solid margins, and AI‑driven automation plans—showing why investors view the lab‑service leader as a resilient, value‑based opportunity.

Quest Diagnostics: Market‑leading diagnostics, CLIA & CAP‑accredited testing, rapid TAT, patient‑centric growth, and solid earnings outlook.

Quest Diagnostics’ FY‑2024 report shows steady 6.3 % revenue growth, 11.8 % margin, and a 15 % ROIC on AI‑driven digital pathology, positioning it for strong 5.6 % FY‑2025 growth.

Quest Diagnostics’ trading snapshot reveals strong cash flow, value‑based revenue growth and strategic lab expansion, while tackling labor shortages, supply chain shocks and tech upgrades to stay ahead of reimbursement shifts.

Quest Diagnostics stays strong—boosting test volumes, cutting costs, and expanding into molecular diagnostics—while delivering solid returns and a solid valuation.